펩티딜프롤릴 cis-trans 이성질체화효소 A : 파이프라인 리뷰

※ 본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

펩티딜프롤릴 cis-trans 이성질체화효소 A(Peptidyl Prolyl Cis Trans Isomerase A)를 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

• 조사 범위

펩티딜프롤릴 cis-trans 이성질체화효소 A 개요

치료제 개발

• 개발중인 제품 : 개발 단계별
• 개발중인 제품 : 치료 영역별
• 개발중인 제품 : 증상별

파이프라인 제품 상황 개요

• 초기 단계 제품

기업에서 개발중인 제품

치료제 평가

• 단독치료 제품/병용요법 제품별
• 작용기전별
• 투여 경로별
• 분자 종류별

치료제 개발 참여기업

• ContraVir Pharmaceuticals Inc
• Cypralis Ltd
• Debiopharm International SA
• Enanta Pharmaceuticals Inc
• Ensemble Therapeutics Corp

약제 개요

• alisporivir
• alisporivir + EDP-239
• CRV-431
• Small Molecules to Inhibit Cyclophilin A for Hepatitis B
• Small Molecules to Inhibit Cyclophilin A for Inflammation

휴지 상태인 프로젝트

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

부록

도표

Summary

Global Markets Direct's, 'Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Pipeline Review, H2 2016', provides in depth analysis on Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted pipeline therapeutics.

The report provides comprehensive information on the Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

• The report provides a snapshot of the global therapeutic landscape for Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8)
• The report reviews Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics and enlists all their major and minor projects
• The report assesses Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

• Table of Contents
  • List of Tables
  • List of Figures
• Introduction
  • Global Markets Direct Report Coverage
• Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) Overview
• Therapeutics Development
  • Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Products under Development by Stage of Development
  • Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Products under Development by Therapy Area
  • Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Products under Development by Indication
• Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Pipeline Products Glance
  • Early Stage Products
• Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Products under Development by Companies
• Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Therapeutics Assessment
  • Assessment by Monotherapy/Combination Products
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
• Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Companies Involved in Therapeutics Development
  • ContraVir Pharmaceuticals Inc
  • Cypralis Ltd
  • Debiopharm International SA
  • Enanta Pharmaceuticals Inc
  • Ensemble Therapeutics Corp
• Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Drug Profiles
  • alisporivir - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • alisporivir + EDP-239 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • CRV-431 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • Small Molecules to Inhibit Cyclophilin A for Hepatitis B - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • Small Molecules to Inhibit Cyclophilin A for Inflammation - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
• Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Dormant Projects
• Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Discontinued Products
• Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Featured News & Press Releases
  • Dec 08, 2016: ContraVirs Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis B
  • Sep 12, 2016: ContraVir Reports New CRV431 Data Highlighting Synergistic Activity with CMX157 Against Hepatitis B
  • Aug 22, 2016: ContraVir to Release New CRV431 Data Highlighting Potential Synergy with CMX157 Against Hepatitis B
  • Apr 19, 2016: Ciclofilin Pharmaceuticals Invited to Present Hepatitis B Drug Data at Cambridge Healthtech Institute's Eleventh Annual Drug Discovery Chemistry Conference
  • Feb 04, 2016: Ciclofilin Pharmaceuticals Welcomes Dr. Nikolai Naoumov to Its Scientific Advisory Board
  • Dec 02, 2015: Ciclofilin Pharmaceuticals Announces Formation of World-Class HBV and Liver Disease Scientific Advisory Board
  • Nov 30, 2015: Ciclofilin Pharmaceuticals to Present at HEP DART 2015
  • Sep 08, 2015: Debiopharm International and Solid Biosciences Announce a Collaboration to Explore the Use of Alisporivir in Muscular Dystrophy
  • Aug 04, 2015: Ciclofilin Pharmaceuticals Receives Notice of Patent Allowance for Novel Cyclophilin Inhibitor
  • Jul 28, 2015: Ciclofilin Pharmaceuticals' Lead Antiviral Drug Reduces Liver HBV DNA
  • Jun 24, 2015: Ciclofilin Pharmaceuticals' HBV Drug Demonstrates Anti-Fibrotic Activity
  • Feb 24, 2015: Ciclofilin Pharmaceuticals Granted Patent in Japan for Cyclophilin Inhibitor Drugs
  • Feb 17, 2015: Ciclofilin Pharmaceuticals to Present HBV/HIV/HCV Co-Infection Results at EASL 2015
  • Nov 13, 2014: The Government of Canada Provides Support to Ciclofilin Pharmaceuticals for the Pre-Clinical Development of Its Lead Drug
  • Nov 04, 2014: Ciclofilin Pharmaceuticals to Present HIV/HCV Co-Infection Results at AASLD in Boston on November 11
• Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

• Number of Products under Development for, H2 2016
• Number of Products under Development by Therapy Area, H2 2016
• Number of Products under Development by Indication, H2 2016
• Comparative Analysis by Early Stage Products, H2 2016
• Number of Products under Development by Companies, H2 2016
• Products under Development by Companies, H2 2016
• Assessment by Monotherapy/Combination Products, H2 2016
• Number of Products by Stage and Mechanism of Action, H2 2016
• Number of Products by Stage and Route of Administration, H2 2016
• Number of Products by Stage and Molecule Type, H2 2016
• Pipeline by ContraVir Pharmaceuticals Inc, H2 2016
• Pipeline by Cypralis Ltd, H2 2016
• Pipeline by Debiopharm International SA, H2 2016
• Pipeline by Enanta Pharmaceuticals Inc, H2 2016
• Pipeline by Ensemble Therapeutics Corp, H2 2016
• Dormant Projects, H2 2016
• Discontinued Products, H2 2016

List of Figures

• Number of Products under Development for, H2 2016
• Number of Products under Development by Therapy Area, H2 2016
• Number of Products under Development by Indication, H2 2016
• Comparative Analysis by Early Stage Products, H2 2016
• Assessment by Monotherapy/Combination Products, H2 2016
• Number of Products by Stage and Mechanism of Actions, H2 2016
• Number of Products by Molecule Types, H2 2016
• Number of Products by Stage and Molecule Type, H2 2016